Evolved bacterial siderophore-mediated antibiotic cross-protection.
Journal
Research square
Titre abrégé: Res Sq
Pays: United States
ID NLM: 101768035
Informations de publication
Date de publication:
18 May 2023
18 May 2023
Historique:
pubmed:
9
6
2023
medline:
9
6
2023
entrez:
9
6
2023
Statut:
epublish
Résumé
Antibiotic cross-protection enables resistant bacteria to protect other bacteria that would be otherwise susceptible to the drug. Cefiderocol is the first siderophore cephalosporin antibiotic approved for treating Gram-negative bacterial infections, including carbapenem-resistant
Identifiants
pubmed: 37292841
doi: 10.21203/rs.3.rs-2644953/v1
pmc: PMC10246284
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NIAID NIH HHS
ID : K22 AI127473
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI151362
Pays : United States